For metastatic NSCLC patients with mixed response to pembrolizumab, would you radiate focal progressing lesions and continue pembrolizumab, add in chemotherapy to pembrolizumab, or discontinue pembrolizumab and move to second line?  


Answer from: Medical Oncologist at Academic Institution